ACT 299--RECOMBINANT INTERLEUKIN 2 IN SYMPTOMATIC HIV INFECTED CHILDREN

ACT 299——重组白细胞介素 2 用于有症状的 HIV 感染儿童

• 批准号: 6116896
• 负责人: Stuart E Starr
• 金额: $ 2.47万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6116896
• 关键词: AIDS therapy; HIV infections; child (0-11); clinical research; clinical trials; human subject; human therapy evaluation; immunotherapy; interleukin 2; outcomes research; pediatric pharmacology; recombinant proteins

CHOP has enrolled three children in this study to date. Nationwide, this study has accrued 10 patients out of its target accrual goal of 27 children. There have been no unanticipated side effects to date. Preliminary data indicate that CD4 cell counts rise about 40% at the lowest dose tested. The second dose level is currently being tested.

迄今为止，CHOP已招募三个孩子参加这项研究。在全国范围内，这个 研究已从其目标应计目标中获得10名患者27例 孩子们。迄今为止，还没有意外的副作用。 初步数据表明，CD4细胞计数在 测试的最低剂量。第二剂量水平当前正在测试中。